vs
ExlService Holdings, Inc.（EXLS）与PHIBRO ANIMAL HEALTH CORP（PAHC）财务数据对比。点击上方公司名可切换其他公司
ExlService Holdings, Inc.的季度营收约是PHIBRO ANIMAL HEALTH CORP的1.5倍（$542.6M vs $373.9M），ExlService Holdings, Inc.净利率更高（11.1% vs 7.3%，领先3.8%），PHIBRO ANIMAL HEALTH CORP同比增速更快（20.9% vs 12.7%），ExlService Holdings, Inc.自由现金流更多（$106.5M vs $8.3M），过去两年PHIBRO ANIMAL HEALTH CORP的营收复合增速更高（19.2% vs 11.5%）
ExlService Holdings Inc.是全球知名的分析与数字解决方案服务商，服务覆盖保险、医疗健康、银行金融服务、媒体、零售等多个行业，总部位于纽约，在美国、欧洲、亚洲、拉美、澳大利亚、南非等地拥有超过5.4万名专业从业人员。
菲宝罗动物保健公司是一家美国动物健康与矿物质营养企业，主营产品涵盖抗菌药、抗球虫药、驱虫药，以及畜禽营养补充剂、疫苗等。公司下设矿物质营养、功能材料、动物健康三大业务板块，收入主要来源于上述板块，业务遍及美国、拉美、加拿大、欧洲、中东、非洲及亚太地区。
EXLS vs PAHC — 直观对比
营收规模更大
EXLS
是对方的1.5倍
$373.9M
营收增速更快
PAHC
高出8.2%
12.7%
净利率更高
EXLS
高出3.8%
7.3%
自由现金流更多
EXLS
多$98.3M
$8.3M
两年增速更快
PAHC
近两年复合增速
11.5%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $542.6M | $373.9M |
| 净利润 | $60.2M | $27.5M |
| 毛利率 | 38.6% | 35.5% |
| 营业利润率 | 14.4% | 13.5% |
| 净利率 | 11.1% | 7.3% |
| 营收同比 | 12.7% | 20.9% |
| 净利润同比 | 18.9% | 762.1% |
| 每股收益（稀释后） | $0.38 | $0.67 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXLSPAHC
| Q4 25 | $542.6M | $373.9M | ||
| Q3 25 | $529.6M | $363.9M | ||
| Q2 25 | $514.5M | $378.7M | ||
| Q1 25 | $501.0M | $347.8M | ||
| Q4 24 | $481.4M | $309.3M | ||
| Q3 24 | $472.1M | $260.4M | ||
| Q2 24 | $448.4M | $273.2M | ||
| Q1 24 | $436.5M | $263.2M |
净利润EXLSPAHC
| Q4 25 | $60.2M | $27.5M | ||
| Q3 25 | $58.2M | $26.5M | ||
| Q2 25 | $66.1M | $17.2M | ||
| Q1 25 | $66.6M | $20.9M | ||
| Q4 24 | $50.7M | $3.2M | ||
| Q3 24 | $53.0M | $7.0M | ||
| Q2 24 | $45.8M | $752.0K | ||
| Q1 24 | $48.8M | $8.4M |
毛利率EXLSPAHC
| Q4 25 | 38.6% | 35.5% | ||
| Q3 25 | 38.5% | 32.9% | ||
| Q2 25 | 37.7% | 29.0% | ||
| Q1 25 | 38.6% | 30.1% | ||
| Q4 24 | 38.1% | 32.9% | ||
| Q3 24 | 37.8% | 32.1% | ||
| Q2 24 | 37.1% | 31.9% | ||
| Q1 24 | 37.4% | 30.2% |
营业利润率EXLSPAHC
| Q4 25 | 14.4% | 13.5% | ||
| Q3 25 | 14.4% | 14.1% | ||
| Q2 25 | 15.8% | 8.9% | ||
| Q1 25 | 15.7% | 9.6% | ||
| Q4 24 | 14.8% | 8.3% | ||
| Q3 24 | 14.7% | 6.8% | ||
| Q2 24 | 13.7% | 6.7% | ||
| Q1 24 | 14.1% | 7.6% |
净利率EXLSPAHC
| Q4 25 | 11.1% | 7.3% | ||
| Q3 25 | 11.0% | 7.3% | ||
| Q2 25 | 12.8% | 4.5% | ||
| Q1 25 | 13.3% | 6.0% | ||
| Q4 24 | 10.5% | 1.0% | ||
| Q3 24 | 11.2% | 2.7% | ||
| Q2 24 | 10.2% | 0.3% | ||
| Q1 24 | 11.2% | 3.2% |
每股收益（稀释后）EXLSPAHC
| Q4 25 | $0.38 | $0.67 | ||
| Q3 25 | $0.36 | $0.65 | ||
| Q2 25 | $0.40 | $0.43 | ||
| Q1 25 | $0.40 | $0.51 | ||
| Q4 24 | $0.31 | $0.08 | ||
| Q3 24 | $0.33 | $0.17 | ||
| Q2 24 | $0.28 | $0.02 | ||
| Q1 24 | $0.29 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $328.4M | $74.5M |
| 总债务越低越好 | $298.6M | $624.2M |
| 股东权益账面价值 | $912.7M | $332.4M |
| 总资产 | $1.7B | $1.4B |
| 负债/权益比越低杠杆越低 | 0.33× | 1.88× |
8季度趋势，按日历期对齐
现金及短期投资EXLSPAHC
| Q4 25 | $328.4M | $74.5M | ||
| Q3 25 | $390.1M | $85.3M | ||
| Q2 25 | $353.3M | $77.0M | ||
| Q1 25 | $331.4M | $70.4M | ||
| Q4 24 | $340.6M | $67.1M | ||
| Q3 24 | $325.8M | $89.8M | ||
| Q2 24 | $276.1M | $114.6M | ||
| Q1 24 | $246.2M | $98.7M |
总债务EXLSPAHC
| Q4 25 | $298.6M | $624.2M | ||
| Q3 25 | $354.8M | $628.0M | ||
| Q2 25 | $260.0M | $631.7M | ||
| Q1 25 | $307.3M | $635.4M | ||
| Q4 24 | $288.5M | $639.1M | ||
| Q3 24 | $344.7M | $295.2M | ||
| Q2 24 | — | $312.1M | ||
| Q1 24 | — | — |
股东权益EXLSPAHC
| Q4 25 | $912.7M | $332.4M | ||
| Q3 25 | $952.4M | $311.7M | ||
| Q2 25 | $1.1B | $285.7M | ||
| Q1 25 | $1.0B | $266.0M | ||
| Q4 24 | $929.9M | $246.8M | ||
| Q3 24 | $907.6M | $258.5M | ||
| Q2 24 | $852.6M | $256.6M | ||
| Q1 24 | $803.3M | $270.1M |
总资产EXLSPAHC
| Q4 25 | $1.7B | $1.4B | ||
| Q3 25 | $1.7B | $1.4B | ||
| Q2 25 | $1.7B | $1.4B | ||
| Q1 25 | $1.7B | $1.3B | ||
| Q4 24 | $1.6B | $1.3B | ||
| Q3 24 | $1.6B | $966.3M | ||
| Q2 24 | $1.5B | $982.2M | ||
| Q1 24 | $1.4B | $979.0M |
负债/权益比EXLSPAHC
| Q4 25 | 0.33× | 1.88× | ||
| Q3 25 | 0.37× | 2.01× | ||
| Q2 25 | 0.25× | 2.21× | ||
| Q1 25 | 0.30× | 2.39× | ||
| Q4 24 | 0.31× | 2.59× | ||
| Q3 24 | 0.38× | 1.14× | ||
| Q2 24 | — | 1.22× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $117.4M | $19.4M |
| 自由现金流经营现金流 - 资本支出 | $106.5M | $8.3M |
| 自由现金流率自由现金流/营收 | 19.6% | 2.2% |
| 资本支出强度资本支出/营收 | 2.0% | 3.0% |
| 现金转化率经营现金流/净利润 | 1.95× | 0.70× |
| 过去12个月自由现金流最近4个季度 | $298.1M | $47.3M |
8季度趋势，按日历期对齐
经营现金流EXLSPAHC
| Q4 25 | $117.4M | $19.4M | ||
| Q3 25 | $120.7M | $9.3M | ||
| Q2 25 | $109.4M | $21.3M | ||
| Q1 25 | $3.2M | $43.2M | ||
| Q4 24 | $105.3M | $3.1M | ||
| Q3 24 | $110.1M | $12.6M | ||
| Q2 24 | $74.9M | $28.4M | ||
| Q1 24 | $-21.9M | $11.4M |
自由现金流EXLSPAHC
| Q4 25 | $106.5M | $8.3M | ||
| Q3 25 | $106.4M | $-4.5M | ||
| Q2 25 | $95.0M | $8.1M | ||
| Q1 25 | $-9.7M | $35.4M | ||
| Q4 24 | $95.3M | $-4.7M | ||
| Q3 24 | $97.3M | $3.0M | ||
| Q2 24 | $62.8M | $15.4M | ||
| Q1 24 | $-33.1M | $1.7M |
自由现金流率EXLSPAHC
| Q4 25 | 19.6% | 2.2% | ||
| Q3 25 | 20.1% | -1.2% | ||
| Q2 25 | 18.5% | 2.1% | ||
| Q1 25 | -1.9% | 10.2% | ||
| Q4 24 | 19.8% | -1.5% | ||
| Q3 24 | 20.6% | 1.2% | ||
| Q2 24 | 14.0% | 5.6% | ||
| Q1 24 | -7.6% | 0.6% |
资本支出强度EXLSPAHC
| Q4 25 | 2.0% | 3.0% | ||
| Q3 25 | 2.7% | 3.8% | ||
| Q2 25 | 2.8% | 3.5% | ||
| Q1 25 | 2.6% | 2.2% | ||
| Q4 24 | 2.1% | 2.5% | ||
| Q3 24 | 2.7% | 3.7% | ||
| Q2 24 | 2.7% | 4.8% | ||
| Q1 24 | 2.6% | 3.7% |
现金转化率EXLSPAHC
| Q4 25 | 1.95× | 0.70× | ||
| Q3 25 | 2.08× | 0.35× | ||
| Q2 25 | 1.66× | 1.24× | ||
| Q1 25 | 0.05× | 2.07× | ||
| Q4 24 | 2.08× | 0.97× | ||
| Q3 24 | 2.08× | 1.81× | ||
| Q2 24 | 1.63× | 37.80× | ||
| Q1 24 | -0.45× | 1.36× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXLS
| Insurance | $185.8M | 34% |
| Healthcare And Life Sciences | $142.2M | 26% |
| Banking Capital Markets And Diversified Industries | $122.6M | 23% |
| International Growth Markets | $92.0M | 17% |
PAHC
| Medicated Feed Additives And Others | $202.1M | 54% |
| Mineral Nutrition | $68.9M | 18% |
| Nutritional Specialties | $50.2M | 13% |
| Vaccines | $37.6M | 10% |
| Performance Products | $15.0M | 4% |
